EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?

Ava J Dorazio iD, Ellen G Kline, Kevin M Squires iD, Jason M Pogue, Daria Van Tyne iD, Ryan K Shields iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01543-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Ava J Dorazio und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cephalosporins, beta-Lactamase Inhibitors, Pseudomonas aeruginosa, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paired baseline and post-exposure isolates from 34 patients who developed ceftolozane–tazobactam (TOL-TAZ) resistance following treatment of multidrug-resistant (MDR) Pseudomonas aeruginosa infections were analyzed to determine if ceftolozane with an alternative β-lactamase inhibitor could restore susceptibility. The median baseline TOL-TAZ MIC was 2 mg/L; 88% of post-exposure isolates harbored new ampC mutations. Median MIC fold-increase from baseline was 32-, 24-, 16-, and 6-fold for ceftolozane–tazobactam, ceftolozane–avibactam (AVI), ceftolozane–relebactam (REL), and ceftolozane–durlobactam (DUR), respectively. Enhanced ceftolozane–durlobactam activity was evident in specific ampC mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cephalosporinsbeta-Lactamase InhibitorsPseudomonas aeruginosaAnti-Bacterial AgentsAzabicyclo CompoundsMicrobial Sensitivity TestsHumansTazobactambeta-LactamasesDrug Resistance, Multiple, BacterialPseudomonas InfectionsBacterial ProteinsPenicillanic AcidDrug CombinationsMutation

Stichwörter der Autor:innen

Pseudomonasavibactamceftolozane–tazobactamdurlobactamrelebactam

Substanzen

Cephalosporinsbeta-Lactamase InhibitorsAnti-Bacterial AgentsAzabicyclo CompoundsTazobactambeta-Lactamasesceftolozane, tazobactam drug combinationceftolozaneBacterial Proteinsrelebactam

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA.
  • Center for Innovative Antimicrobial Therapy, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Ava J Dorazio, Kevin M Squires, Daria Van Tyne, Ryan K Shields

Förderung

  • NIAID NIH HHS

Zitieren

APA

Dorazio, A. J., Kline, E. G., Squires, K. M., Pogue, J. M., Van Tyne, D., & Shields, R. K. (2025). Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01543-24

Vancouver

Dorazio AJ, Kline EG, Squires KM, Pogue JM, Van Tyne D, Shields RK. Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01543-24

BibTeX
@article{Dorazio2025,
  author = {Dorazio, Ava J and Kline, Ellen G and Squires, Kevin M and Pogue, Jason M and Van Tyne, Daria and Shields, Ryan K},
  title = {Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01543-24}
}
Kostenlos starten →